Unusual Neurotoxicity Associated with Amiodarone Therapy
Arch Int Med 147:881-884, Palakurthy,P.R.,et al, 1987
Trial of Globus Pallidus Focused Ultrasound Ablation in Parkinsons Disease
NEJM 388:683-693, 759, Krishna,V.,et al, 2023
Trial of Botulinum Toxin for Isolated or Essential Head Tremor
NEJM 389:1753-1765, Marques,A.,et al, 2023
A 59-Year-Old Woman Presenting with Diplopia, Dysarthria, Right-sided Weakness, and Encephalopathy
Neurol 97:e859-e864, Manzano, G.S.,et al, 2021
Tardive Diaphragmatic Tremor
Neurol 94:e656, Gupta, H.V., 2020
A 54-year-old woman with Dementia, Myoclonus, and Ataxia
Neurol 89:e7-e12, Ali, F.,et al, 2017
Withdrawing Amantadine in Dyskinetic Patients with Parkinson Disease
Neurol 82:300-307, Ory-Magne, F.,et al, 2014
Serotonin Syndrome
BMJ 348:g1626, Buckley, N.A.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Antipsychosis Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1208, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Serotonin Reuptake Inhibitors and Related Drugs
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014
Disorders of the Nervous System Caused by Drugs, Toxins, and Chemical Agents, Lithium
Adams & Victors Principles of Neurology Chp 43, pg 1212, Ropper, A.H.,et al, 2014
Neurostimulation for Parkinsons Disease with Early Motor Complications
NEJM 368:610-622, Rau, W.,et al, 2013
Movement Disorders Emergencies Part 1
, Robottom, B.J., et al, 2011
Evidence-based guideline update: Treatment of Essential Tremor
Neurol 77:1752-1755, Zesiewicz, T.A.,et al, 2011
Frequency, Characteristics, and Risk Factors for Amiodarone Neurotoxicity
Arch Neurol 66:865-869, Orr,C.F. &Ahlskog,E., 2009
Parkinsons Disease
Lancet 373:2055-2066, Lees,A.J.,et al, 2009
Reversible Parkinsonism and Ataxia Associated With High-Dose Octreotide
Neurol 70:2345-2346, Espay,A.J., 2008
Clinical Update:Diagnosis and Treatment of Essential Tremor
Lancet 369:1152-1154, Benito-Leon,J&Louis,E.D., 2007
Treatment Options in the Modern Management of Parkinson Disease
Arch Neurol 64:1083-1088, Schapira,A.H.V., 2007
A 75-Year-Old Man With Cognitive Impairment and Gait Changes, Lewy Body Disease
Neurol 69:1183-1189, Lippa,C.F.,et al, 2007
Cetirizine-Induced Dystonic Movements
Neurol 66:143-144, Rajput,A. &Baerg,K., 2006
What is the Risk of Developing Parkinsonism Following Neuroleptic Use?
Neurol 66:941-943, Noyes,K.,et al, 2006
Dystonia
NEJM 355:818-829, Tarsy,D. &Simon,D.K., 2006
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Reversible Parkinsonism with Normal B-CIT-SPECT in Patients Exposed to Sodium Valproate
Neurol 62:1435-1437, Easterford,K.,et al, 2004
Treatment of Wilson Disease With Ammonium Tetrathiomolybdate, III. Initial Therapy in a Total of 55 Neurologically Affected Patients and Follow-up With Zinc Therapy
Arch Neurol 60:379-385, Brewer,G.J.,et al, 2003
The Risk-Benefit Profile of Commonly Used Herbal Therapies: Ginkgo, St. John's Wort, Genseng, Echinacea, Saw Palmetto, and Kava
Ann Int Med 136:42-53, Ernst,E., 2002
A Double-blind Placebo-controlled Trial of Topiramate Treatment for Essential Tremor
Neurol 59:132-134, Connor,G.S., 2002
Drug-Induced Pisa Syndrome (Pleurothotomus)
CNS Drugs 10:166-174, Suzuki, T. & Matsuzaka, H., 2002
Myoclonus Secondary to Albuterol (Salbutamol) instillation
Neurol 54:2022-2023, Micheli,F.,et al, 2000
A Five-Year Study of the Incidence of Dyskinesia in Patients With Early Parkinson's Disease who were Treated with Ropinirole or Levodopa
NEJM 342:1484-1491, Rascol,O.,et al, 2000
Serotonin Sydrome
Medicine 79:201-209, Mason,P.J. et al, 2000
A Case of Lithium-Induced Asterixis
J Am Geriatr Society 48:457, Stewart,J.T. & Williams, L.S., 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Parkinsonism after Taking Ecstasy
NEJM 340:1443, Mintzer,S.,et al, 1999
Lamotrigine-Induced Tourettism
Neurol 52:1191-1194, Lombroso,C.T., 1999
Acute Dystonia Induced by Drug Treatment
BMJ 319:623-626, vanHarten,P.N.,et al, 1999
Tardive Dyskinesia:Diagnosis, Pathogenesis, and Management
The Neurologist 4:180-187, Trugman,J.M., 1998
Olanzapine Can Worsen Parkinsonism
Neurol 50:1183-1184, Jimenez-Jimenez,F.J.,et al, 1998
Olanzapine in the Treatment of Dopaminomimetic Psychosis in Patients with Parkinson's Disease
Neurol 50:1195-1196, Wolters,E.C.,et al, 1998
Dystonia and Chorea in Acquired Systemic Disorders
JNNP 65:436-445, Janavs,J.L.&Aminoff,M.J., 1998
Parkinson's Disease
NEJM 339:1044-1053,1130-1143, Lang,A.E.&Lozano,A.M., 1998
Drug-Induced Movement Disorders
Neurol Clin 16:125-139, Diederich,N.J. & Goetz,C.G., 1998
Long-Term Effects of Tetrabenazine in Hyperkinetic Movement Disorders
Neurol 48:358-362, Jankovic,J.&Beach,J., 1997
Tremor Caused by Trimethoprim-Sulfamethoxazole in a Patient with AIDS
Neurol 48:537-538, VanGerpen,J.A., 1997
Managing the Late Complications of Parkinson's Disease
Neurol 49:549-557, Waters,C.H., 1997
Basal Ganglia Infarction in a Child with Disulfiram Poisoning
Pediatrics 99:605-608, Mahajan,P.&Kottamasu,S., 1997
Choreoathetosis as a Side Effect of Gabapentin Therapy in Severely Neurologically Impaired Patients
Arch Neurol 54:910-912, Chudnow,R.S.,et al, 1997
A Survey of Antidepressant Drug Use in Parkinson's Disease
Neurol 49:1168-1170, Richard,I.H.,et al, 1997